Literature DB >> 33427938

Maturation of neuronal AD-tau pathology involves site-specific phosphorylation of cytoplasmic and synaptic tau preceding conformational change and fibril formation.

Luis Aragão Gomes1,2, Valerie Uytterhoeven3,4, Diego Lopez-Sanmartin5,3,6, Sandra O Tomé5,3, Thomas Tousseyn7, Rik Vandenberghe3,8,9, Mathieu Vandenbulcke3,10, Christine A F von Arnim11,12, Patrik Verstreken3,4, Dietmar Rudolf Thal13,14,15.   

Abstract

In Alzheimer's disease (AD), tau-protein undergoes a multi-step process involving the transition from a natively unfolded monomer to large, aggregated structures such as neurofibrillary tangles (NFTs). However, it is not yet clear which events initiate the early preclinical phase of AD tauopathy and whether they have impact on the propagation of tau pathology in later disease stages. To address this question, we analyzed the distribution of tau species phosphorylated at T231, S396/S404 and S202/T205, conformationally modified at the MC1 epitope and fibrillary tau detected by the Gallyas method (Gallyas-tau), in the brains of 15 symptomatic and 20 asymptomatic cases with AD pathology as well as of 19 nonAD cases. As initial tau lesions, we identified phosphorylated-T231-tau diffusely distributed within the somatodendritic compartment (IC-tau) and phosphorylated-S396/pS404-tau in axonal lesions of the white matter and in the neuropil (IN-tau). The subcellular localization of pT231-tau in the cell body and pS396/pS404-tau in the presynapse was confirmed in hP301L mutant Drosophila larvae. Phosphorylated-S202/T205-tau, MC1-tau and Gallyas-tau were negative for these lesions. IC- and IN-tau were observed in all analyzed regions of the human brain, including early affected regions in nonAD cases (entorhinal cortex) and late affected regions in symptomatic AD cases (cerebellum), indicating that tau pathology initiation follows similar processes when propagating into previously unaffected regions. Furthermore, a sequence of AD-related maturation of tau-aggregates was observed, initiated by the appearance of IC- and IN-tau, followed by the formation of pretangles exhibiting pT231-tau, pS396/pS404-tau and pS202/pT205-tau, then by MC1-conformational tau, and, finally, by the formation of Gallyas-positive NFTs. Since cases classified as nonAD [Braak NFT stages < I (including a-1b)] already showed IC- and IN-tau, our findings suggest that these lesions are a prerequisite for the development of AD.

Entities:  

Keywords:  Neuropathology; Preclinical Alzheimer’s disease; Site-specific phosphorylation; Tau modification; Tau-protein

Year:  2021        PMID: 33427938     DOI: 10.1007/s00401-020-02251-6

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  63 in total

1.  Reversible paired helical filament-like phosphorylation of tau is an adaptive process associated with neuronal plasticity in hibernating animals.

Authors:  Thomas Arendt; Jens Stieler; Arjen M Strijkstra; Roelof A Hut; Jan Rüdiger; Eddy A Van der Zee; Tibor Harkany; Max Holzer; Wolfgang Härtig
Journal:  J Neurosci       Date:  2003-08-06       Impact factor: 6.167

2.  Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years.

Authors:  Heiko Braak; Dietmar R Thal; Estifanos Ghebremedhin; Kelly Del Tredici
Journal:  J Neuropathol Exp Neurol       Date:  2011-11       Impact factor: 3.685

3.  The pathological process underlying Alzheimer's disease in individuals under thirty.

Authors:  Heiko Braak; Kelly Del Tredici
Journal:  Acta Neuropathol       Date:  2010-12-15       Impact factor: 17.088

4.  Demonstration of amyloid deposits and neurofibrillary changes in whole brain sections.

Authors:  H Braak; E Braak
Journal:  Brain Pathol       Date:  1991-04       Impact factor: 6.508

5.  Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease.

Authors:  Jean C Augustinack; Anja Schneider; Eva-Maria Mandelkow; Bradley T Hyman
Journal:  Acta Neuropathol       Date:  2002-01       Impact factor: 17.088

6.  Accumulation of abnormally phosphorylated tau precedes the formation of neurofibrillary tangles in Alzheimer's disease.

Authors:  C Bancher; C Brunner; H Lassmann; H Budka; K Jellinger; G Wiche; F Seitelberger; I Grundke-Iqbal; K Iqbal; H M Wisniewski
Journal:  Brain Res       Date:  1989-01-16       Impact factor: 3.252

7.  A sequence of cytoskeleton changes related to the formation of neurofibrillary tangles and neuropil threads.

Authors:  E Braak; H Braak; E M Mandelkow
Journal:  Acta Neuropathol       Date:  1994       Impact factor: 17.088

8.  Interlaboratory comparison of assessments of Alzheimer disease-related lesions: a study of the BrainNet Europe Consortium.

Authors:  Irina Alafuzoff; Maria Pikkarainen; Safa Al-Sarraj; Thomas Arzberger; Jeanne Bell; Istvan Bodi; Nenad Bogdanovic; Herbert Budka; Orso Bugiani; Isidro Ferrer; Ellen Gelpi; Giorgio Giaccone; Manuel B Graeber; Jean-Jacques Hauw; Wouter Kamphorst; Andrew King; Nicolas Kopp; Penelope Korkolopoulou; Gábor G Kovács; David Meyronet; Piero Parchi; Efstratios Patsouris; Matthias Preusser; Rivka Ravid; Wolfgang Roggendorf; Danielle Seilhean; Nathalie Streichenberger; Dietmar R Thal; Hans Kretzschmar
Journal:  J Neuropathol Exp Neurol       Date:  2006-08       Impact factor: 3.685

9.  Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry.

Authors:  Heiko Braak; Irina Alafuzoff; Thomas Arzberger; Hans Kretzschmar; Kelly Del Tredici
Journal:  Acta Neuropathol       Date:  2006-08-12       Impact factor: 17.088

10.  Staging of neurofibrillary pathology in Alzheimer's disease: a study of the BrainNet Europe Consortium.

Authors:  Irina Alafuzoff; Thomas Arzberger; Safa Al-Sarraj; Istvan Bodi; Nenad Bogdanovic; Heiko Braak; Orso Bugiani; Kelly Del-Tredici; Isidro Ferrer; Ellen Gelpi; Giorgio Giaccone; Manuel B Graeber; Paul Ince; Wouter Kamphorst; Andrew King; Penelope Korkolopoulou; Gábor G Kovács; Sergey Larionov; David Meyronet; Camelia Monoranu; Piero Parchi; Efstratios Patsouris; Wolfgang Roggendorf; Danielle Seilhean; Fabrizio Tagliavini; Christine Stadelmann; Nathalie Streichenberger; Dietmar R Thal; Stephen B Wharton; Hans Kretzschmar
Journal:  Brain Pathol       Date:  2008-03-26       Impact factor: 6.508

View more
  10 in total

1.  Selective disruption of Drp1-independent mitophagy and mitolysosome trafficking by an Alzheimer's disease relevant tau modification in a novel Caenorhabditis elegans model.

Authors:  Sanjib Guha; Anson Cheng; Trae Carroll; Dennisha King; Shon A Koren; Sierra Swords; Keith Nehrke; Gail V W Johnson
Journal:  Genetics       Date:  2022-08-30       Impact factor: 4.402

2.  Rose Bengal inhibits β-amyloid oligomers-induced tau hyperphosphorylation via acting on Akt and CDK5 kinases.

Authors:  Chen-Ye Mou; Yan-Fei Xie; Jia-Xin Wei; Qi-Yao Wang; Jing-Yang Le; Yong-Jie Bao; Pan-Pan Zhang; Yue-Chun Mao; Xing-Han Huang; Han-Bo Pan; C Benjamin Naman; Lin Liu; Hong-Ze Liang; Xiang Wu; Jia Xu; Wei Cui
Journal:  Psychopharmacology (Berl)       Date:  2022-10-12       Impact factor: 4.415

Review 3.  Deciphering the Structure and Formation of Amyloids in Neurodegenerative Diseases With Chemical Biology Tools.

Authors:  Isabelle Landrieu; Elian Dupré; Davy Sinnaeve; Léa El Hajjar; Caroline Smet-Nocca
Journal:  Front Chem       Date:  2022-05-12       Impact factor: 5.545

4.  Reassessment of Neuronal Tau Distribution in Adult Human Brain and Implications for Tau Pathobiology.

Authors:  Giavanna Paterno; Brach M Bell; Kimberly-Marie M Gorion; Stefan Prokop; Benoit I Giasson
Journal:  Acta Neuropathol Commun       Date:  2022-06-28       Impact factor: 7.578

5.  The Reduction of Tau Hyperphosphorylation by Cornel Iridoid Glycosides Is Mediated by Their Influence on Calpain Activity.

Authors:  Kaiwen Guo; Cuicui Yang; Lan Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2022-01-20       Impact factor: 2.629

6.  Changes in the language system as amyloid-β accumulates.

Authors:  Mariska Reinartz; Silvy Gabel; Jolien Schaeverbeke; Karen Meersmans; Katarzyna Adamczuk; Emma Susanne Luckett; Steffi De Meyer; Koen Van Laere; Stefan Sunaert; Patrick Dupont; Rik Vandenberghe
Journal:  Brain       Date:  2021-12-31       Impact factor: 13.501

Review 7.  Tau Post-Translational Modifications: Potentiators of Selective Vulnerability in Sporadic Alzheimer's Disease.

Authors:  Trae Carroll; Sanjib Guha; Keith Nehrke; Gail V W Johnson
Journal:  Biology (Basel)       Date:  2021-10-15

8.  Long-Term Depression-Inducing Low Frequency Stimulation Enhances p-Tau181 and p-Tau217 in an Age-Dependent Manner in Live Rats.

Authors:  Yangyang Zhang; Yin Yang; Zhengtao Hu; Manyi Zhu; Shuangying Qin; Pengpeng Yu; Bo Li; Jitian Xu; Tomas Ondrejcak; Igor Klyubin; Michael J Rowan; Neng-Wei Hu
Journal:  J Alzheimers Dis       Date:  2022       Impact factor: 4.160

9.  Spatiotemporal characterization of cellular tau pathology in the human locus coeruleus-pericoerulear complex by three-dimensional imaging.

Authors:  Abris Gilvesy; Evelina Husen; Zsofia Magloczky; Orsolya Mihaly; Tibor Hortobágyi; Shigeaki Kanatani; Helmut Heinsen; Nicolas Renier; Tomas Hökfelt; Jan Mulder; Mathias Uhlen; Gabor G Kovacs; Csaba Adori
Journal:  Acta Neuropathol       Date:  2022-08-30       Impact factor: 15.887

Review 10.  Tau interactome and RNA binding proteins in neurodegenerative diseases.

Authors:  Tomas Kavanagh; Aditi Halder; Eleanor Drummond
Journal:  Mol Neurodegener       Date:  2022-10-17       Impact factor: 18.879

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.